Abstract: To investigate effects of Rosiglitazone on activities of AMPK (AMPactivated protein kinase)，GLUT4 (glucose transport 4)，IRS1 (insulin receptor substrate 1)， and PPARγ (peroxisome proliferator activated receptor γ) in the skeletal muscle of highfat fed rats. MethodsMale Wistar rats were randomly divided into three groups：the control group (N, n=10), the highfat diet group (HF, n=10), and the Rosiglitazonetreated group (HF+Ros，n=10). After a high fat feeding for four months, rats in the HF+Ros group were treated with Rosiglitazone at a dose of 1?mg/(kg·d) orally for one month. Skeletal muscles of all animals were gained for further analysis. The mRNA levels of AMPKα1, AMPKα2, and GLUT4 were determined using real time PCR and of IRS1 and PPARγ using RTPCR. Protein levels of total AMPK, PAMPK, and GLUT4 were determined by Western blot. ResultsCompared with the controls, the mRNA levels of AMPKα2, GLUT4, and PPARγ were reduced, and also protein expressions of total AMPK, PAMPK and GLUT4 were decreased in rats with a highfat diet. But the AMPKα1 and IRS1 mRNA levels had no changes. Compared with the HF group, Rosiglitazone increased mRNA levels of GLUT4, PPARγ and IRS1 and enhanced protein expressions of PAMPK and GLUT4. But there were no changes in AMPKα1, AMPKα2, and TAMPK. ConclusionRosiglitazone could increase expression of PAMPK, GLUT4, PPARγ, and IRS1 in highfat fed rats, which suggests that it could ameliorate insulin resistance.

Key words: Rosiglitazone, AMPactivated protein kinase, Highfat, Rats，Wistar